Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Black Diamond Therapeutics

11/08/2023 13:34

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 52 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 54 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 52 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Black Diamond Therapeutics Inc shares had fallen by 32.5%
this
quarter and gained 89.4% so far this year.
    * The company reported a quarterly loss of $19.15 million.
    * Wall Street's median 12-month price target for Black
Diamond
Therapeutics Inc is $10.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 11 at 12:34 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.54          -0.52          Beat
 Mar. 31 2023      -0.61          -0.57          Beat
 Dec. 31 2022      -0.63          -0.59          Beat
 Sep. 30 2022      -0.64          -0.60          Beat